An interventional study of Lidocaine and Normal saline in Organ Protection, sponsored by General Hospital of Ningxia Medical University. Status unknown. Open to participants aged 65 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-08-16.
Sponsored by General Hospital of Ningxia Medical University · Not applicable, Interventional, and Prevention
The purpose of this study is to investigate the effects of intravenous lidocaine on serum miRNA-135a and its downstream proteins Rock2 and Add1 in elderly patients undergoing non-cardiac under general anesthesia.
Postoperative cognitive dysfunction (POCD) is a major complication following surgeries and anesthesia, especially in elderly individuals. Lidocaine, an inexpensive, widely available, and relatively safe compound, is a local anesthetic that readily crosses the blood-brain barrier. Intravenous lidocaine can reduce the incidence of POCD. However, the mechanism is still unclear.
Rock2 and Add1, which are regulated by miRNA-135a, play a key role in learning, memory, and cognition.
The objective of this study is to investigate the efficacy of intravenous lidocaine on the incidence of early POCD, and the levels of Rock2, Add1, and miRNA-135a in elderly patients undergoing non-cardiac under general anesthesia.
269 studies on the registry are indexed under Postoperative Cognitive Complications; 56 are open to participants now.
This study's planned enrollment of 50 is below the median of 110 across 150 interventional studies indexed under Postoperative Cognitive Complications.
Browse Postoperative Cognitive Complications studies →General Hospital of Ningxia Medical University is the lead sponsor of 106 studies on the registry; 40 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the first hour, 1.5 mg/kg for the second hour, 0.7 mg/kg until the end of the surgery.
Drug: Lidocaine
Normal saline administered as a bolus and an infusion with identical volume and rate changes as the treatment group.
Drug: Normal saline
Intravenous bolus of 1.5 mg/kg of lidocaine followed by a continuous infusion of 3.0 mg/kg for the frst hour, 1.5 mg/kg for the second hour, 0.7 mg/kg until the end of the surgery.
Patients are received equal volumes of saline intravenously until the end of the surgery
Changes from Baseline miRNA-135A at the end of surgery immediately and 1, 3days after surgery
Venous blood was extracted, and the serum miRNA-135a level of patients were detected by PCR and ELISA before surgery, at the end of surgery, 1day and 3day after surgery
Time frame: at preoperation, at the end of surgery immediately, 1day and 3day after surgery
Changes from Baseline Rock2 at the end of surgery immediately and 1, 3days after surgery
Venous blood was extracted, and the serum Rock2 level of patients were detected by PCR and ELISA before surgery, at the end of surgery, 1day and 3day after surgery
Time frame: at preoperation, at the end of surgery immediately, 1day and 3day after surgery
Changes from Baseline Add1 at the end of surgery immediately and 1, 3days after surgery
Venous blood was extracted, and the serum Add1 level of patients were detected by PCR and ELISA before surgery, at the end of surgery, 1day and 3day after surgery
Time frame: at preoperation, at the end of surgery immediately, 1day and 3day after surgery
Changes from Baseline mini-mental state examination (MMSE) at the end of surgery immediately and 1, 3days after surgery
MMSE was performed
Time frame: at preoperation,1day and 3day after surgery
Postoperative cognitive dysfunction (POCD)
the incidence of POCD
Time frame: at preoperation,1day and 3day after surgery
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Sep 2022; primary completion for Sep 2023, 12 months later.
Of 59 non-industry interventional studies with no phase under Postoperative Cognitive Complications, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's planned 12 months is below that.
Counting every sponsor, half of 59 studies reached it within 15 months; a quarter within 8 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lidocaine
Postoperative Cognitive Complications →
General Hospital of Ningxia Medical University →